Literature DB >> 10881992

Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle.

N Teramoto1, P Gogolák, N Nagy, A Maeda, K Kvarnung, T Björkholm, E Klein.   

Abstract

OBJECTIVES: To understand the mechanism for the refractoriness of B-chronic lymphocyte leukemia (B-CLL) cells for EBV-induced immortalization. STUDY DESIGN/
METHODS: Cells from four B-CLL patients were infected with Epstein-Barr virus (EBV). Noninfected and infected aliquots were exposed to CD40L. Five days later, the cultures were analyzed for cell survival, activation, DNA synthesis, and expression of EBV-encoded and of cellular regulatory proteins retinoblastoma (Rb), p53, recombinant sequence binding protein (RBP)Jk, and PU.1. The proteins were detected by immunoblotting and by immunofluorescence.
RESULTS: A proportion of the cells were activated and expressed Epstein-Barr nuclear antigens (EBNAs) and elevated Rb level but not latent membrane protein (LMP)-1 and p53. They did not enter the cell cycle. Exposure to CD40L induced DNA synthesis but it did not modify the expression of the EBNAs.
CONCLUSIONS: The virus could activate CLL cells, but the full course of the early events that leads to immortalization--as seen in normal B cells--did not proceed beyond a certain point. Compared to B lymphocytes, the critical point is between activation and initiation of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881992

Source DB:  PubMed          Journal:  J Hum Virol        ISSN: 1090-9508


  8 in total

1.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

2.  EBV infection induces expression of the transcription factors ATF-2/c-Jun in B lymphocytes but not in B-CLL cells.

Authors:  Kentaro Bandobashi; Anquan Liu; Noémi Nagy; Loránd L Kis; Jun Nishikawa; Magnus Björkholm; George Klein; Eva Klein
Journal:  Virus Genes       Date:  2005-05       Impact factor: 2.332

3.  CD34+ cord blood cell-transplanted Rag2-/- gamma(c)-/- mice as a model for Epstein-Barr virus infection.

Authors:  Mario Cocco; Cristiana Bellan; Roxane Tussiwand; Davide Corti; Elisabetta Traggiai; Stefano Lazzi; Susanna Mannucci; Lucio Bronz; Nazzareno Palummo; Chiara Ginanneschi; Piero Tosi; Antonio Lanzavecchia; Markus G Manz; Lorenzo Leoncini
Journal:  Am J Pathol       Date:  2008-10-09       Impact factor: 4.307

4.  Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.

Authors:  Carlo Visco; Erika Falisi; Ken H Young; Michela Pascarella; Omar Perbellini; Giuseppe Carli; Elisabetta Novella; Davide Rossi; Ilaria Giaretta; Chiara Cavallini; Maria Teresa Scupoli; Anita De Rossi; Emanuele Stefano Giovanni D'Amore; Mario Rassu; Gianluca Gaidano; Giovanni Pizzolo; Achille Ambrosetti; Francesco Rodeghiero
Journal:  Oncotarget       Date:  2015-07-30

5.  EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency.

Authors:  Eva Klein; Noémi Nagy; Abu Eahsan Rasul
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

6.  Written in Blood: Kissing Disease miRNAs Could Predict Outcome of Patients With Chronic Lymphocytic Leukaemia.

Authors:  Charles H Lawrie
Journal:  EBioMedicine       Date:  2015-05-12       Impact factor: 8.143

7.  Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia.

Authors:  Jin-Hua Liang; Rui Gao; Yi Xia; Robert Peter Gale; Rui-Ze Chen; Yu-Qiong Yang; Li Wang; Xiao-Yan Qu; Hai-Rong Qiu; Lei Cao; Min Hong; Rong Wang; Yan Wang; Lei Fan; Yao-Yu Chen; Zhi-Bin Hu; Jian-Yong Li; Wei Xu
Journal:  Oncotarget       Date:  2016-01-12

8.  Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients.

Authors:  Julie Morscio; Emilie Bittoun; Nathalie Volders; Eveline Lurquin; Iwona Wlodarska; Olivier Gheysens; Peter Vandenberghe; Gregor Verhoef; Philippe Demaerel; Daan Dierickx; Xavier Sagaert; Ann Janssens; Thomas Tousseyn
Journal:  J Hematop       Date:  2016-05-21       Impact factor: 0.196

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.